Cargando…

Analysis of recreational psychedelic substance use experiences classified by substance

RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hase, Adrian, Erdmann, Max, Limbach, Verena, Hasler, Gregor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799548/
https://www.ncbi.nlm.nih.gov/pubmed/35031816
http://dx.doi.org/10.1007/s00213-022-06062-3
_version_ 1784642085761056768
author Hase, Adrian
Erdmann, Max
Limbach, Verena
Hasler, Gregor
author_facet Hase, Adrian
Erdmann, Max
Limbach, Verena
Hasler, Gregor
author_sort Hase, Adrian
collection PubMed
description RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states and processes derived from recreational use-based online experience reports. METHODS: Using 2947 publicly available online reports, we compared Ayahuasca and N,N-dimethyltryptamine (DMT, analyzed together), ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin (mushroom), and antidepressant drug use experiences. We examined word frequencies related to various psychological states and processes and semantic proximity to psychedelic and mystical experience scales. RESULTS: Linguistic markers of psychological function indicated distinct effect profiles. For example, MDMA experience reports featured an emotionally intensifying profile accompanied by many cognitive process words and dynamic-personal language. In contrast, Ayahuasca and DMT experience reports involved relatively little emotional language, few cognitive process words, increased analytical thinking-associated language, and the most semantic similarity with psychedelic and mystical experience descriptions. LSD, psilocybin mushroom, and ketamine reports showed only small differences on the emotion-, analytical thinking-, psychedelic, and mystical experience-related language outcomes. Antidepressant reports featured more negative emotional and cognitive process-related words, fewer positive emotional and analytical thinking-related words, and were generally not similar to mystical and psychedelic language. CONCLUSION: This article addresses an existing research gap regarding the comparison of different psychedelic drugs on linguistic profiles of psychological states, processes, and experiences. The large sample of experience reports involving multiple psychedelic drugs provides valuable information that would otherwise be difficult to obtain. The results could inform experimental research into psychedelic drug effects in healthy populations and clinical trials for psychedelic treatments of psychiatric problems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-022-06062-3.
format Online
Article
Text
id pubmed-8799548
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87995482022-02-02 Analysis of recreational psychedelic substance use experiences classified by substance Hase, Adrian Erdmann, Max Limbach, Verena Hasler, Gregor Psychopharmacology (Berl) Original Investigation RATIONALE AND OBJECTIVES: Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states and processes derived from recreational use-based online experience reports. METHODS: Using 2947 publicly available online reports, we compared Ayahuasca and N,N-dimethyltryptamine (DMT, analyzed together), ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin (mushroom), and antidepressant drug use experiences. We examined word frequencies related to various psychological states and processes and semantic proximity to psychedelic and mystical experience scales. RESULTS: Linguistic markers of psychological function indicated distinct effect profiles. For example, MDMA experience reports featured an emotionally intensifying profile accompanied by many cognitive process words and dynamic-personal language. In contrast, Ayahuasca and DMT experience reports involved relatively little emotional language, few cognitive process words, increased analytical thinking-associated language, and the most semantic similarity with psychedelic and mystical experience descriptions. LSD, psilocybin mushroom, and ketamine reports showed only small differences on the emotion-, analytical thinking-, psychedelic, and mystical experience-related language outcomes. Antidepressant reports featured more negative emotional and cognitive process-related words, fewer positive emotional and analytical thinking-related words, and were generally not similar to mystical and psychedelic language. CONCLUSION: This article addresses an existing research gap regarding the comparison of different psychedelic drugs on linguistic profiles of psychological states, processes, and experiences. The large sample of experience reports involving multiple psychedelic drugs provides valuable information that would otherwise be difficult to obtain. The results could inform experimental research into psychedelic drug effects in healthy populations and clinical trials for psychedelic treatments of psychiatric problems. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00213-022-06062-3. Springer Berlin Heidelberg 2022-01-15 2022 /pmc/articles/PMC8799548/ /pubmed/35031816 http://dx.doi.org/10.1007/s00213-022-06062-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Investigation
Hase, Adrian
Erdmann, Max
Limbach, Verena
Hasler, Gregor
Analysis of recreational psychedelic substance use experiences classified by substance
title Analysis of recreational psychedelic substance use experiences classified by substance
title_full Analysis of recreational psychedelic substance use experiences classified by substance
title_fullStr Analysis of recreational psychedelic substance use experiences classified by substance
title_full_unstemmed Analysis of recreational psychedelic substance use experiences classified by substance
title_short Analysis of recreational psychedelic substance use experiences classified by substance
title_sort analysis of recreational psychedelic substance use experiences classified by substance
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799548/
https://www.ncbi.nlm.nih.gov/pubmed/35031816
http://dx.doi.org/10.1007/s00213-022-06062-3
work_keys_str_mv AT haseadrian analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance
AT erdmannmax analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance
AT limbachverena analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance
AT haslergregor analysisofrecreationalpsychedelicsubstanceuseexperiencesclassifiedbysubstance